CC
ADAP

CQS Cayman’s Adaptimmune Therapeutics ADAP Stock Holding History

CQS Cayman’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,558
Closed -$231K – 155
2015
Q2 		$231K Buy
+12,558
New +$216K 0.01% 171

Other funds holding ADAP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

CQS Cayman's ADAP Position: Q3 2015 in Review

CQS Cayman sold out of Adaptimmune Therapeutics (ADAP) in Q3 2015, closing a stake of 12,558 shares — an estimated $231K sold.

CQS Cayman first reported a position in ADAP in Q2 2015 and held it in 1 quarter. The position peaked at $231K in Q2 2015. 41 funds tracked by Wall St. Rank hold ADAP as of Q3 2015.

  • CQS Cayman reported no remaining Adaptimmune Therapeutics position as of Q3 2015 after selling out during the quarter.
  • CQS Cayman sold 12,558 Adaptimmune Therapeutics shares in Q3 2015, an estimated $231K.
  • CQS Cayman first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 1 quarter.
  • CQS Cayman's Adaptimmune Therapeutics position peaked at $231K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2015.

Based on CQS Cayman's 13F filing for Q3 2015, filed 30 Oct 2015.